STUDY QUESTION: Is corifollitropin alfa 150 μg equivalent to follitropin beta 300 IU/day for controlled ovarian hyperstimulation (COS) in older women weighing ≥50 kg undergoing IVF and/or ICSI in Vietnam?
Introduction
Controlled ovarian stimulation (COS) with gonadotropins is the first step in each cycle of in IVF/ICSI. The effectiveness of this approach is dependent on maintenance of adequate daily levels of FSH during COS. This can be challenging due to the short elimination half-life and rapid metabolic clearance of the traditional agents used in this setting, including hMG and recombinant FSH (rFSH). As a result, these agents need to be administered daily for the duration of stimulation (Fauser and Van Heusden, 1997) .
A novel recombinant hormone has been developed to overcome the issues associated with short product half-life. The pharmacokinetic profile of the new agent, corifollitropin alfa, differs from that of rFSH. It shows slower absorption to peak serum levels and has a half-life of up to 68 hours (Fares et al., 1992; Duijkers et al., 2002; Devroey et al., 2004; Fauser et al., 2009) . As a result, a single dose of corifollitropin alfa has prolonged activity over a full week, compared with the requirement for daily injections of rFSH (Fares et al., 1992; Bouloux et al., 2001; Duijkers et al., 2002) . The ability to provide COS for 1 week with a single dose rather than daily injections reduces the burden of IVF treatment for patients, which in turn could contribute to reduced patient drop-out and improved effectiveness of assisted reproductive technologies (Verberg et al., 2008) .
A single dose of corifollitropin alfa administered early in the follicular phase of the cycle can stimulate and sustain the development of multiple follicles over a 1-week period (Corifollitropin Alfa Dose-finding Study Group, 2008; Fauser et al., 2009) . Corifollitropin alfa has been shown to be associated with similar outcomes to rFSH in several randomized, controlled clinical trials (Corifollitropin Alfa Dose-finding Study Group, 2008; Devroey et al., 2009; Corifollitropin Alfa Ensure Study Group, 2010; Boostanfar et al., 2015) , and this equivalence has been highlighted in a meta-analysis (Griesinger et al., 2016a,b) . In addition, corifollitropin alfa is well tolerated, with no immunogenicity issues (Norman et al., 2011) .
Our centre currently performs~7000 IVF/ICSI cycles a year, and about one-quarter of treated women are aged ≥35 years and weigh ≤60 kg. These patients usually receive a GnRH antagonist protocol and undergo COS with rFSH 200-300 IU/day. The Pursue study found no significant difference in number of oocytes retrieved, implantation rate and vital pregnancy rate between patients who received COS with corifollitropin alfa compared with follitropin beta in Western patients aged ≥35-42 years and weighing ≥50 kg (Boostanfar et al., 2015) . However, Asian patients differ from predominantly Caucasian populations in a number of important ways, including a lower BMI (WHO Expert Consultation, 2004) , higher body fat percentage at the same BMI (Deurenberg et al., 2002) , and diminished ovarian reserve (Lan et al., 2013; Bleil et al., 2014; Iglesias et al., 2014) .
Therefore, we replicated the Pursue study in a local population to compare the efficacy and safety of corifollitropin alfa 150 μg and rFSH (follitropin beta) 300 IU/day for COS in patients from Vietnam aged 35-42 years with a body weight of ≥50 kg undergoing IVF and/or
WHAT DOES THIS MEANS FOR PATIENTS?
Ovarian stimulation is a key part of IVF treatment and this study investigates whether the use of a longer-lasting drug to stimulate the ovaries works as well as the standard daily injections used to do this.
The new drug is absorbed more slowly so one dose lasts seven days which would make the process easier for patients. Some trials have suggested that it works as well as standard drugs, but these studies have focused on Western women. In contrast, this trial was carried out in Vietnam where the researchers wanted to know if the previous results would be replicated in Asian women. The women in this trial had a lower body weight and a similar age to, or were slightly older than, those in the previous studies.
Women who were having IVF were randomized to have controlled ovarian stimulation with either standard treatment or the longer-lasting drug. The study found that there were no significant differences between the two groups in the number of eggs the women produced or in pregnancy or live birth rates.
ICSI. The aim was to generate data to better inform clinical management of this group of patients.
Materials and Methods
This randomized controlled trial with an equivalence design (NCT02466204) was conducted from 19 June 2015 to 10 August 2016 at IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.
Ethical approval
The Institutional Review Board (IRB) approved the study protocol on 18 May 2015 (IRB reference number: 06/QĐ-CGRH-NCKH&ĐT). Ethical Committee approval was obtained on 26 May 2015 (reference number: 03/15/ĐĐ-BVMĐ). All patients provided written informed consent to participate in the study, which was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization guidelines for Good Clinical Practice, and local regulatory requirements.
Study population
Patients were undergoing a routine ART cycle. Those who provided written informed consent and satisfied all the inclusion and none of the exclusion criteria (Table I) were enroled in the trial.
Randomization and sample size
Eligible subjects were randomized in blocks of four via computergenerated lists to ovarian stimulation with either corifollitropin alfa (Elonva ® ) 150 μg or follitropin beta (Puregon ® ) 300 IU/day for 7 days. After a patient agreed to participate to the study, the investigator contacted an administrator not involved in the study who opened a sealed envelope and informed the investigator of the randomization group (corifollitropin alfa or follitropin beta). The sample size was calculated based on a between-group difference in the number of oocytes retrieved from −3 to +5 being clinically equivalent. For comparing mean values between groups with α = 0.05, power of 90% and assuming a standard deviation of almost 8 for the number of oocytes retrieved, the required sample size was calculated as 150 patients per group. Assuming a dropout rate of 20%, the sample size was set at 200 per group (400 subjects overall).
Study treatments
Participants in the corifollitropin alfa group received a single subcutaneous (SC) injection of corifollitropin alfa 150 mg in 0.5 mL on Day 2 or 3 of the menstrual cycle. Those in the follitropin beta group received daily SC injections of follitropin beta 300 IU/day starting on Day 2 or 3 of the menstrual cycle (stimulation 
IVF protocol
From stimulation Day 8 onwards, subjects in both treatment groups continued with a daily SC dose of follitropin beta up to the day before administration of hCG or the day of GnRH agonist administration. Lower follitropin beta doses could be used if deemed appropriate, but the maximum dose daily dose was 300 IU. A GnRH antagonist (ganirelix acetate 0.25 mg in 0.5 mL SC) was started on Day 5 of stimulation in both groups to prevent premature LH surges. As soon as ≥3 follicles of 17 mm in diameter were observed on ultrasound scan (USS), recombinant hCG was given for final oocyte maturation; a GnRH agonist (triptorelin) was used when there were >19 follicles of ≥11 mm on the day of trigger to avoid ovarian hyperstimulation syndrome (OHSS) (Griesinger et al., 2016a,b) . Ovum pick-up (OPU) followed by ICSI was performed~34-36 h later. Two or three embryos were transferred 3 days after OPU. The centre operates 7 days a week, and OPU as possible on each and every day of the week.
Patients given recombinant hCG for final oocyte maturation received luteal phase support with intra-vaginal progesterone gel (90 mg twice daily), started on the day of OPU. When a GnRH agonist was used to trigger final oocyte maturation, luteal support was given as above with the addition of progesterone 50 mg intramuscular injection daily and estradiol (2 mg/day orally, four times daily), or all embryos could be frozen for later transfer.
Outcome measures
The primary endpoint was the number of oocytes retrieved. Secondary endpoints were the number of MII oocytes, the number of two pronuclear (2PN) fertilized oocytes, the number of follicles >11 mm in diameter on the day of hCG administration, estradiol level on the day of hCG administration, the FSH dose (daily dose, days and total dose), the rate of cycle cancellation prior to hCG due to poor response or hyper-response, the rate of moderate and severe OHSS, the implantation rate (defined as the number of sacs with heart beat per total number of embryos transferred), rates of clinical pregnancy, ongoing pregnancy, cumulative ongoing pregnancy, multiple pregnancy, live birth, cumulative live birth and obstetric outcomes (hypertension, diabetes mellitus, delivery rate at <24, <32, <37 and ≥37 weeks, reasons for delivery and birthweight). Clinical safety was assessed by recording the occurrence of serious adverse events (including moderate and severe OHSS), and local injection site tolerance.
Assessments
USS and blood sampling were performed on stimulation Day 5 in the follitropin beta group, on Day 8 in the corifollitropin group, and on the day of hCG or GnRH agonist administration. Measures of injection site tolerance were assessed by clinic staff at 30 min after injection of study medication.
A serum beta hCG test was performed at least 17 days after OPU. In patients with a positive test, vaginal and/or abdominal USS was performed at 5-6 weeks after embryo transfer to confirm a clinical pregnancy and at ≥10 weeks to confirm an ongoing pregnancy.
The severity of OHSS was determined based on a classification adapted from Mathur (Royal College of Obstetrics and Gynaecology, 2006) (Mathur, 2006) .
Statistical analysis
The study was designed as an equivalence trial. The null hypothesis was that there is no difference between the corifollitropin alfa and follitropin beta groups with respect to the number of oocytes retrieved. Values were compared using the Student's t-test, with a P-value of 0.05 as the threshold for statistical significance. All efficacy analyses were performed on an intention-to-treat basis, including all randomized patients who received corifollitropin alfa or at least one dose of rFSH. Rates were compared by calculating relative risks and 95% CI. Between-group differences in noncontinuous and continuous variables were assessed using the Fisher's exact test and Student's t-test, respectively. Safety analyses included all treated subjects who received corifollitropin alfa or follitropin beta. The percentage of patients with moderate or severe OHSS in each treatment group was compared using Fisher's exact test. Kaplan-Meier curves were constructed to estimate cumulative ongoing pregnancy rate at 12 months after randomization. The two groups were compared using a log-rank test and Cox regression model. All analyses were performed using the R statistical package (R version 3.3.1). P-values were calculated two-sided, and P < 0.05 was considered statistically significant.
Results
Of 4186 eligible patients, a total of 400 patients were enroled in the study, 200 in each treatment group. A CONSORT flow diagram is shown in Fig. 1 . Patient demographic data at baseline did not differ significantly between the corifollitropin alfa and follitropin beta treatment groups (Table II) . Clinical and cycle characteristics are shown in Table III . The duration of stimulation was one day longer in the corifollitropin alfa vs follitropin beta group (10 vs 9 days; P < 0.001), and the number of follicles ≥11 or ≥14 mm was significantly greater (both P < 0.001) (Table III) . In terms of hormone levels, estradiol on the day of trigger and the number of cycles with a premature progesterone rise were significantly higher in the corifollitropin alfa group (P = 0.022 and P = 0.048, respectively, vs follitropin beta) (Table III) . Four cycles were cancelled at the patients' request (3 in the corifollitropin alfa group and one in the follitropin beta group). Values are mean ± standard deviation, or number of patients (%).
Number of oocytes retrieved
There was no significant difference between the corifollitropin alfa and follitropin beta groups in the numbers of oocytes retrieved, MII oocytes and fertilized oocytes (Table III) .
Fertility and pregnancy outcomes
Corifollitropin alfa was non-inferior to follitropin beta with respect to the cumulative ongoing pregnancy rate (hazard ratio 0.97, 95% CI: 0.69-1.38; P = 0.83) (Fig. 2) , and live birth rate per initiated cycle at 12 months after randomization (30.5 vs 32.0%; P = 0.88). Outcomes in the two groups were similar when analyzed per embryo transfer, per initiated cycle and per initiated cycle at 12 months after randomization (Table IV) .
Safety
OHSS was documented in 2 patients (1%) in the corifollitropin alfa group and 1 patient (0.5%) in the follitropin beta group. Rates of other complications and obstetric outcomes were similar in the two treatment groups when analyzed per embryo transfer, per initiated cycle and per initiated cycle at 12 months after randomization (Table V) . No injection site reactions were observed during the study. Values are mean ± standard deviation, or number of patients (%).
OHSS, ovarian hyperstimulation syndrome.
Discussion
This randomized, controlled clinical trial demonstrates that corifollitropin alfa 150 μg was equivalent to treatment with follitropin beta 300 IU/day with respect to the number of oocytes retrieved, the ongoing, cumulative ongoing and live birth rates, and obstetric outcomes in older, low body weight women from Vietnam. Patients in the corifollitropin alfa group had a significantly higher number of follicles ≥11 and ≥14 mm in diameter than those in the follitropin beta group, and also significantly higher levels of progesterone and estradiol. This is consistent with data showing that an increased number of follicles is associated with higher hormone levels (Kyrou et al., 2012) . Our results showing no significant differences in outcomes between corifollitropin alfa and follitropin beta in women undergoing IVF are consistent with those of previous randomized, controlled studies (Corifollitropin Alfa Dose-finding Study Group, 2008; Devroey et al., 2009; Corifollitropin Alfa Ensure Study Group, 2010; Boostanfar et al., 2015) . Of these, the trial most similar to ours was the Pursue study (Boostanfar et al., 2015) , which used the same age and body weight inclusion criteria to define eligible patients, and the same drugs and dosages. Despite the similar inclusion criteria, mean body weight in our study (53 kg) was lower than that in the Pursue study (66-68 kg), possibly reflecting the different ethnicities of the two populations. In addition, our patients had a higher baseline antiMüllerian hormone (AMH) levels than the Pursue population (3.9 vs 1.8 ng/mL, respectively), although the antral follicle count (AFC) was similar (10-11 in both trials). Despite the differences in patient baseline characteristics, the findings of the two trials were almost identical in terms of the number of oocytes retrieved (11.4 and 10.8 with corrifollitropin alfa and follitropin beta in our study vs 10.7 and 10.3 in the Pursue trial), ongoing pregnancy rate (25 and 23% vs 22 and 24%) and implantation rate (20 and 18% vs 19 and 21%) (Boostanfar et al., 2015) . We also reported the cumulative ongoing pregnancy rate based on the potential for higher numbers of oocytes after COS with corifollitropin alfa, which could lead to an increase in the cumulative pregnancy rate. Our data showed an increase of one oocyte in the corifollitropin alfa vs follitropin beta group, but the cumulative pregnancy rate in the two treatment arms was similar. Another difference compared with the Pursue trial was the comparative duration of stimulation in the two treatment groups. This was similar in both the Pursue (Boostanfar et al., 2015) and Engage ) studies (in the latter about one-third of patients in the corifollitropin alfa group did not need any FSH top-up doses), but one day longer in the corifollitropin alfa vs follitropin beta group in our study. The reason for this is not yet known.
Patients in the Ensure trial (Corifollitropin Alfa Ensure Study Group, 2010) had a similar bodyweight to those included in our study (i.e. usually below 60 kg) and the results of that study also showed the equivalent oocyte numbers for corifollitropin alfa and rFSH. In the Ensure trial, patients were younger than in our trial (mean 31 vs 38 years) and lower dosages of both corifollitropin alfa (100 μg) and follitropin beta (150 IU/ day) were used. The lower corifollitropin alfa dosage was based on modelling data showing that the 100 μg dose in patients weighing ≤60 kg provided drug exposure equivalent to that achieved after a 150 μg dose in those weighing >60 kg (De Greef et al., 2007 ). An analysis of data from the Pursue trial in older women (age 35-42 years) (Boostanfar et al., 2015) and the Engage trial in younger women (age 18-36 years) , both of which used corifollitropin alfa and follitropin beta doses of 150 μg and 200 IU/day in Ensure and ≤300 IU/day in Pursue, respectively, showed no significant differences in the fertilization rate, number of embryos obtained, and number of good quality embryos obtained between patient subgroups based on BMI (≤25 vs > 25 kg/m 2 ) (Schieber et al., 2013) . Ours is the first study to investigate the equivalence of corifollitropin alfa and follitropin beta in a group of Asian patients with both low body weight and older age. Additional strengths of the study are the reporting of Continued obstetric outcomes after up to four embryo transfers over a follow-up period of 1 year. However, there are a number of limitations that need to be taken into account when interpreting the results. The findings are only applicable to patients and populations similar to those enroled in the trial, i.e. Asian women aged 35-42 years weighing ≥50 kg. However, similar results showing the equivalence of corifollitropin alfa and rFSH have been obtained in younger and heavier patients of different ethnicities , Corifollitropin Alfa Ensure Study Group, 2010 , Boostanfar et al., 2015 , suggesting that a single dose of corifollitropin alfa may be an appropriate option for COS in patient with a range of characteristics. Also, all patients in the current study underwent ICSI, as is common practice in Asia, so the results only apply when this technique is used. Finally, the study had an open-label design and therefore the potential for bias cannot be excluded.
In conclusion, this study shows that a single injection of corifollitropin alfa 150 μg is an effective and equivalent alternative to follitropin beta 300 IU/day for COS in older women with lower body weight from Vietnam, and adds to the body of evidence for the equivalence of the two treatments in a range of patients. Corifollitropin alfa is an attractive option for women because it reduces the burden of COS therapy, and is better for healthcare professionals because it requires fewer staff resources for drug administration and monitoring while providing equivalent outcomes. Values are mean ± standard deviation, or number of patients (%).
